DDInter1620 DDInter448
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Ropivacaine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Ropivacaine {u} (Compound) downregulates {v} (Gene) PTK2
PTK2 {u} (Gene) is bound by {v} (Compound) Crizotinib
Ropivacaine {u} (Compound) upregulates {v} (Gene) WDR7
WDR7 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Ropivacaine {u} (Compound) downregulates {v} (Gene) NSDHL
NSDHL {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Ropivacaine {u} (Compound) downregulates {v} (Gene) CD320
CD320 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Ropivacaine {u} (Compound) causes {v} (Side Effect) Respiratory failure
Respiratory failure {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Ropivacaine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) PTK2B
PTK2B {u} (Gene) is bound by {v} (Compound) Crizotinib
Ropivacaine {u} (Compound) downregulates {v} (Gene) PTK2
PTK2 {u} (Gene) interacts with {v} (Gene) IGF1R
IGF1R {u} (Gene) is bound by {v} (Compound) Crizotinib
Ropivacaine {u} (Compound) upregulates {v} (Gene) WDR7
WDR7 {u} (Gene) is regulated by {v} (Gene) ABL2
ABL2 {u} (Gene) is bound by {v} (Compound) Crizotinib
Ropivacaine {u} (Compound) downregulates {v} (Gene) NSDHL
NSDHL {u} (Gene) regulates {v} (Gene) PRKD3
PRKD3 {u} (Gene) is bound by {v} (Compound) Crizotinib
Ropivacaine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Ropivacaine (Compound) downregulates PTK2 (Gene) and PTK2 (Gene) is bound by Crizotinib (Compound)
Ropivacaine (Compound) upregulates WDR7 (Gene) and WDR7 (Gene) is upregulated by Crizotinib (Compound)
Ropivacaine (Compound) downregulates NSDHL (Gene) and NSDHL (Gene) is upregulated by Crizotinib (Compound)
Ropivacaine (Compound) downregulates CD320 (Gene) and CD320 (Gene) is downregulated by Crizotinib (Compound)
Ropivacaine (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by Crizotinib (Compound)
Ropivacaine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is bound by Crizotinib (Compound)
Ropivacaine (Compound) downregulates PTK2 (Gene) and PTK2 (Gene) interacts with IGF1R (Gene) and IGF1R (Gene) is bound by Crizotinib (Compound)
Ropivacaine (Compound) upregulates WDR7 (Gene) and WDR7 (Gene) is regulated by ABL2 (Gene) and ABL2 (Gene) is bound by Crizotinib (Compound)
Ropivacaine (Compound) downregulates NSDHL (Gene) and NSDHL (Gene) regulates PRKD3 (Gene) and PRKD3 (Gene) is bound by Crizotinib (Compound)